FMP
Jul 3, 2024 10:29 PM - Davit Kirakosyan(Last modified: Jul 4, 2024 4:25 AM)
Image credit: FMP
Canaccord Genuity analysts revised their price target for Rocket Pharmaceuticals (NASDAQ:RCKT) down to $40 from $49, while maintaining a Buy rating on the stock. The analysts expressed increased confidence in the success of the Phase 3 trial for DESCARTES-08, leading to a 50% assumed success rate. The price target adjustment also accounts for the additional shares from the $130 million PIPE financing.
The analysts anticipate further trial design refinements in Phase 3, such as excluding seronegative and LRP4+ patients from the primary efficacy analysis, which is expected to enhance the trial's likelihood of success.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 16, 2024 8:06 PM - Gordon Thompson
On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...